SCHEMBL665474

SCHEMBL665474

O=C(NC1=CC(=O)C2OC2C1O)c1cc(Cl)c(Cl)cc1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.49
P2RX1 P51575 8/20 0.36
P2RX4 Q99571 5/20 0.36
P2RX7 Q99572 5/20 0.36
TMPRSS4 Q9NRS4 5/20 0.35
KCNMA1 Q12791 4/20 0.33
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 2/20 0.33
MAPT P10636 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
MAPK1 P28482 1/20 0.33
NOD2 Q9HC29 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
NPY1R P25929 1/20 0.33
HTT P42858 1/20 0.33
NPY2R P49146 1/20 0.33
RAB9A P51151 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL665039 0.88 PARK7 (0.50) PARK7P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL666185 0.88 P2RX1 (0.51) PARK7P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL666669 0.85 PARK7 (0.53) PARK7P2RX1P2RX4P2RX7TMPRSS4
SCHEMBL666087 0.84 PARK7 (0.64) PARK7KDM4ENPC1MAPTMEN1
SCHEMBL665288 0.81 PARK7 (0.53) PARK7P2RX1P2RX4P2RX7TMPRSS4
Dehydroxymethylepoxyquinomicin SCHEMBL1669417 0.81 PARK7 (0.54) PARK7P2RX1P2RX4P2RX7KCNMA1
Dehydroxymethylepoxyquinomicin SCHEMBL1671089 0.81 PARK7 (0.54) PARK7P2RX1P2RX4P2RX7KCNMA1
Dehydroxymethylepoxyquinomicin SCHEMBL14491796 0.81 PARK7 (0.54) PARK7P2RX1P2RX4P2RX7KCNMA1
Dehydroxymethylepoxyquinomicin SCHEMBL14504317 0.81 PARK7 (0.54) PARK7P2RX1P2RX4P2RX7KCNMA1
SCHEMBL167099 0.81 PARK7 (0.50) PARK7P2RX1TMPRSS4KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046357-A1 Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) PROFECTUS BIOSCIENCES, INC. (US) 2012-02-23 US claimed
US-20120046357-A1 Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) PROFECTUS BIOSCIENCES, INC. (US) 2012-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046357-A1 Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB) NFKBIA, IKBKB, NFKB1 PARK7 3384/4885P2RX1 855/4885P2RX4 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.